Equities

Ami Organics Ltd

AMIORG:NSI

Ami Organics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,631.30
  • Today's Change91.30 / 5.93%
  • Shares traded663.09k
  • 1 Year change+27.05%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 11:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform3
Hold1
Sell0
Strong Sell0

Share price forecast in INR

The 4 analysts offering 12 month price targets for AMI Organics Ltd have a median target of 1,487.00, with a high estimate of 1,810.00 and a low estimate of 1,250.00. The median estimate represents a -8.33% decrease from the last price of 1,622.20.
High11.6%1,810.00
Med-8.3%1,487.00
Low-22.9%1,250.00

Dividends

In 2024, Ami Organics Ltd reported a dividend of 3.00 INR, equaling last years dividend. The 2 analysts covering the company expect dividends of 3.65 INR for the upcoming fiscal year, an increase of 21.67%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in INR

On May 10, 2024, earnings of 6.94 per share. This result was in line with the expectation of the one analyst following the company
Average growth rate+18.32%
AMI Organics Ltd reported annual 2024 earnings of 20.41 per share on May 10, 2024.
Average growth rate-1.01%
More ▼

Revenue history & estimates in INR

AMI Organics Ltd had 1st quarter 2025 revenues of 1.77bn. This missed the 1.79bn estimate of the one analyst following the company. This was 24.11% above the prior year's 1st quarter results.
Average growth rate+7.83%
AMI Organics Ltd had revenues for the full year 2024 of 7.17bn. This was 16.33% above the prior year's results.
Average growth rate+17.45%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.